DBV Technologies S.A. (EPA:DBV)
France · Delayed Price · Currency is EUR 1.904
-0.056 (-2.86%)
Oct 2, 2026, 5:35 PM CET
DBV Technologies Revenue
DBV Technologies had revenue of $700.00K USD in the quarter ending June 30, 2026, a decrease of -53.33%. This brings the company's revenue in the last twelve months to $5.02M, up 29.26% year-over-year. In the year 2025, DBV Technologies had annual revenue of $5.64M with 35.77% growth.
Revenue (ttm)
$5.02M
Revenue Growth
+29.26%
P/S Ratio
127.82
Revenue / Employee
$29.52K
Employees
170
Market Cap
563.42M EUR
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.64M | 1.49M | 35.77% |
| Dec 31, 2024 | 4.15M | -11.58M | -73.61% |
| Dec 31, 2023 | 15.73M | 10.88M | 224.69% |
| Dec 31, 2022 | 4.84M | -864.00K | -15.14% |
| Dec 31, 2021 | 5.71M | -5.57M | -49.38% |
| Dec 31, 2020 | 11.28M | -3.43M | -23.33% |
| Dec 31, 2019 | 14.71M | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Valneva SE | 142.94M |
| Genfit | 60.21M |
| Cellectis | 55.86M |
| MedinCell | 24.28M |
| Nanobiotix | 11.51M |
| Innate Pharma | 9.81M |
| Sensorion | 6.16M |
| Transgene | 5.62M |
DBV Technologies News
- 2 days ago - DBV Technologies Files FDA Biologics License Application for Viaskin Peanut Patch (DBVT) - GuruFocus
- 2 days ago - DBV Seeks FDA Approval For VIASKIN Peanut Patch In Young Children - Nasdaq
- 2 days ago - DBV Submits BLA For VIASKIN Peanut Patch In Children With Peanut Allergy - Nasdaq
- 3 days ago - DBV Technologies submits BLA to FDA for Viaskin Peanut Patch - TheFly
- 3 days ago - DBV Technologies S.A.: DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN Peanut Patch in Children Aged 4-7 Years - Finanz Nachrichten
- 3 days ago - DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 Years - GlobeNewsWire
- 17 days ago - DBV Technologies Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 23 days ago - DBV Technologies Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts